PEAK6 Investments’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-1,600
Closed -$143K 4473
2023
Q3
$143K Buy
+1,600
New +$143K ﹤0.01% 3245
2023
Q2
Sell
-1,600
Closed -$132K 4214
2023
Q1
$132K Sell
1,600
-1,400
-47% -$113K ﹤0.01% 3377
2022
Q4
$236K Sell
3,000
-3,300
-52% -$265K ﹤0.01% 3163
2022
Q3
$466K Buy
+6,300
New +$452K ﹤0.01% 2938
2022
Q1
Sell
-10,000
Closed -$530K 5506
2021
Q4
$530K Sell
10,000
-19,500
-66% -$1.19M ﹤0.01% 3160
2021
Q3
$2.08M Buy
29,500
+5,100
+21% +$322K ﹤0.01% 1915
2021
Q2
$1.63M Buy
+24,400
New +$1.73M ﹤0.01% 2094
2021
Q1
Sell
-74,400
Closed -$8.84M 5113
2020
Q4
$8.84M Sell
74,400
-12,200
-14% -$1.31M 0.02% 735
2020
Q3
$7.56M Buy
86,600
+52,700
+155% +$4.61M 0.02% 730
2020
Q2
$3.04M Buy
33,900
+23,800
+236% +$2.4M 0.01% 1159
2020
Q1
$1.01M Buy
+10,100
New +$1.1M 0.01% 1532
2019
Q4
Sell
-11,100
Closed -$1.4M 3645
2019
Q3
$1.4M Buy
11,100
+4,700
+73% +$597K 0.01% 1513
2019
Q2
$770K Buy
6,400
+6,300
+6,300% +$620K 0.01% 1973
2019
Q1
$9K Sell
100
-11,800
-99% -$1.07M ﹤0.01% 3641
2018
Q4
$1.19M Sell
11,900
-7,700
-39% -$809K 0.01% 1629
2018
Q3
$2.25M Buy
+19,600
New +$2.03M 0.01% 1351

Other funds holding HAE

PEAK6 Investments's HAE Position: Q3 2024 in Review

PEAK6 Investments sold out of Haemonetics (HAE) in Q3 2024, closing a stake of 3,202 shares — an estimated $265K sold.

PEAK6 Investments first reported a position in HAE in Q3 2018 and held it in 16 quarters. The position peaked at $1.7M in Q3 2021. 306 funds tracked by Wall St. Rank hold HAE as of Q3 2024.

  • PEAK6 Investments reported no remaining Haemonetics position as of Q3 2024 after selling out during the quarter.
  • PEAK6 Investments sold 3,202 Haemonetics shares in Q3 2024, an estimated $265K.
  • PEAK6 Investments first reported a position in Haemonetics in Q3 2018 and held it in 16 quarters.
  • PEAK6 Investments's Haemonetics position peaked at $1.7M in Q3 2021.
  • 306 funds tracked by Wall St. Rank held Haemonetics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.